The case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of The National Institute of Clinical Excellence (NICE).

Br J Cancer · 2002 · PMC2376159 · PMID 12189541

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The differences between these regimens did not reach statistical significance, but there was a trend towards a worse overall survival duration in the paclitaxel/gemcitabine arm.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.